UBS Group AG cut its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 5.2% during the first quarter, Holdings Channel reports. The firm owned 21,491 shares of the company’s stock after selling 1,181 shares during the period. UBS Group AG’s holdings in TherapeuticsMD were worth $155,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Greenwood Capital Associates LLC increased its stake in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the period. American International Group Inc. increased its stake in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the period. Teachers Advisors LLC increased its stake in TherapeuticsMD by 1.4% in the first quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock worth $4,605,000 after buying an additional 9,077 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock worth $207,000 after buying an additional 10,330 shares during the period. Finally, OppenheimerFunds Inc. increased its stake in TherapeuticsMD by 2.4% in the first quarter. OppenheimerFunds Inc. now owns 1,460,315 shares of the company’s stock worth $10,514,000 after buying an additional 33,906 shares during the period.
TherapeuticsMD Inc (NASDAQ:TXMD) traded down 0.36% during trading on Thursday, hitting $5.55. The stock had a trading volume of 129,018 shares. The firm’s 50-day moving average price is $5.44 and its 200-day moving average price is $5.52. TherapeuticsMD Inc has a 1-year low of $3.50 and a 1-year high of $8.30. The stock’s market cap is $1.13 billion.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 71.36% and a negative net margin of 530.84%. The business had revenue of $4.25 million during the quarter, compared to analyst estimates of $4.91 million. During the same period last year, the company earned ($0.11) earnings per share. TherapeuticsMD’s quarterly revenue was down 3.4% compared to the same quarter last year. On average, equities research analysts predict that TherapeuticsMD Inc will post ($0.44) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2800108/ubs-group-ag-has-155000-position-in-therapeuticsmd-inc-nasdaqtxmd.html.
TXMD has been the topic of a number of analyst reports. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $15.00 price target on shares of TherapeuticsMD in a research note on Monday, April 17th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research report on Monday, April 24th. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. CIBC reiterated a “market perform” rating and set a $12.00 target price on shares of TherapeuticsMD in a research report on Tuesday, May 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $33.00 target price on shares of TherapeuticsMD in a research report on Wednesday, May 10th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $16.14.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.